Chemotherapy for hormonally refractory advanced prostate carcinoma. A Comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

✍ Scribed by John A. Laurie; Richard G. Hahn; Terry M. Therneau; Shreyaskumar R. Patel; James A. Mailliard; Harold E. Windschitl; Donald I. Twito; Roscoe F. Morton; James E. Krook

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 398 KB
• Volume: 69
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19920315)69:6<1440::aid-cncr2820690622>3.0.co;2-9

✦ Synopsis

One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil(5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, ie., mitomycin C, followed by doxorubicin on disease progression, followed by 5-FU. Objective tumor regressions were observed in 10 of 70 (14%) patients receiving the FAM treatment arm and 10 of 72 (14%) patients initially receiving mitomycin C. Of the 24 patients who received secondary therapy with doxorubicin alone, 3 (12.5%)

From the